Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 51Completed 49Recruiting 42Unknown 26Terminated 17Withdrawn 10Not yet recruiting 6Suspended 1Enrolling by invitation 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

Specimen Handling 8Magnetic Resonance Spectroscopy 7Biopsy 5Nivolumab 4Capecitabine 4Vincristine 3Radiosurgery 3Paclitaxel 3Irinotecan 3Fluorouracil 3Everolimus 3Docetaxel 3Dexamethasone 3Cyclophosphamide 3Cisplatin 3Bevacizumab 3trifluridine tipiracil drug combination 2spartalizumab 2pembrolizumab 2lenvatinib 2daratumumab 2Taxes 2Radiation 2Prednisone 2Pemetrexed 2Oxaliplatin 2Mitoxantrone 2Leucovorin 2Injections 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Suspended × olaparib × Clear all
NCT03375307 2026-05-13

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

National Cancer Institute (NCI)

Phase 2 Suspended
60 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡